Antibodies, ADCs and peptides: Benchling’s multi-modality coverage for modern pipelines
Thursday, December 3, 2026, – (Europe/London)
Room: Threadneedle Hub · Product Deep Dive
A look at how Benchling's expanding R&D platform supports a broader range of drug modalities — from novel antibody formats to hybrid modalities like antibody-drug conjugates — and what that means for your discovery workflows.
Speakers
-
Head of Scientific Modalities Product Management, Benchling -
Digital Lab Transformation Lead, Drug Discovery Sciences, Bayer